Ecdysterone vs Enclomiphene
Moderate Research vs Well Studied
avoid Mechanism-based · 64% Both Ecdysterone and Enclomiphene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Ecdysterone Enclomiphene
Weight 480.64 Da 405.96 Da
Half-life ~4-9 hours ~10 hours
Type Ecdysteroid (C27H44O7) Trans-isomer of clomifene (selective estrogen receptor modulator)
Key Benefits
Ecdysterone
01 Activation of muscle protein synthesis through ERbeta/PI3K/Akt/mTOR signaling without androgen receptor binding
02 Statistically significant increases in lean muscle mass demonstrated in a controlled human trial in trained subjects
03 No hormonal suppression -- does not affect testosterone, LH, or FSH levels, eliminating the need for post-cycle therapy
04 No androgenic side effects (no hair loss, acne, prostate issues, or virilization in women)
05 No hepatotoxicity, unlike oral anabolic steroids that undergo 17-alpha alkylation
06 Naturally occurring in common foods (spinach, quinoa), with a long history of safe dietary exposure
07 Compatible with other performance compounds due to its non-hormonal mechanism
08 Available as a dietary supplement without prescription in most jurisdictions
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Dosing Protocols
Ecdysterone
500-1000 mg/day (oral) or 50-100 mg/day (injectable) / 1-2x daily
Enhanced Anabolic Effect / Higher Bioavailability 50-100 mg/day Once daily
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Side Effects
Ecdysterone
Mild gastrointestinal discomfort (nausea, bloating, or stomach upset) with oral doses, particularly at higher dosages taken without food
Injection site pain, redness, or mild swelling with injectable administration
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Contraindications
Known allergy to ecdysteroids or spinach-derived compounds
Pregnancy and breastfeeding (insufficient safety data)
Individuals with estrogen-sensitive conditions should consult a physician, though ERbeta activation is generally considered protective rather than proliferative
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Research Evidence
Ecdysterone Enclomiphene
Status Moderate Research Well Studied
References 5 studies 5 studies
Latest 2020 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.